Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Diagnostic tests: (A) molecular testing; or (B) slit lamp examination, serum ceruloplasmin (CP), and 24-hour urine copper; and (C) liver biopsy ... of amylase and lipase Children: 50–75 mg ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short, totaling ...